Миопатический синдром в детской кардиоревматологии, критерии дифференциальной диагностики (лекция)
DOI:
https://doi.org/10.15574/SP.2016.80.84Ключевые слова:
миопатический синдром, дети, дифференциальная диагностика, ювенильный дерматомиозитАннотация
Дифференциальная диагностика миопатического синдрома у детей представляет большие трудности. В статье рассмотрены основные причини миопатического синдрома, его дифференциальная диагностика и лабораторно-инструментальные методы исследования. Представлены современные диагностические критерии ювенильного дерматомиозита и подходы к его лечению.
Ключевые слова: миопатический синдром, дети, дифференциальная диагностика, ювенильный дерматомиозит.
Библиографические ссылки
Antelava OA. 2013. Paraneoplasticheskiy miozit. Osobennosti debyuta, klinicheskoy kartinyi, techeniya, steroid-responsivnosti. Nauchno-prakticheskaya revmatol. 2: 181—185.
Berezhnyi VV, Marushko TV, Marushko YuV. 2009. Klinichna revmatolohiia dytiachoho viku. Cherkasy, Vydavets Chabanenko Yu: 192.
Bondarenko IV, Muhin NA, Nasonov EL. 2005. Porazhenie legkih pri polimiozite i dermatomiozite. Interstitsialnyie zabolevaniya legkih. Ruk-vo dlya vrachey. Pod red MM Ilkovicha, AN Kokosova. Sankt-Peterburg, Nordmedizdat: 274—287.
Busheneva SN, Kadyikov AS, Piradov MA. 2005. Miofastsialnyiy sindrom: ot teorii k praktike. Rossiyskiy med zhurn. 13; 22: 1457—62.
Vnutrennie bolezni po Tinsli-Harrisonu. Pod red E Fauchi, Yu Braunvalda. Kiev, Isselbahera; Moskva, Praktika. 2005.
Gvozdik M. 2006. Differentsialnaya diagnostika i lechenie pri myishechnom sindrome. Zdorov'ya UkraYini. 24: 1.
Antelava OA, Kasatkina LF, Gurkina GT et al. 2004. Differentsialnaya diagnostika myishechnoy slabosti: obzor. Rossiyskiy med zhurn. 14: 854—862.
Dudnyk VM, Bereznyckyi AV, Vyzhga YV. 2015. Evaluation of the intensity of the pain syndrome in kids with juvenile rheumatoid arthritis with clinical presentation of the secondary myopathy. Sovremennaya pediatriya. 6(70): 70—72.
Isaeva LA, Zhvaniya MA. 1978. Dermatomiozit u detey. Moskva, Meditsina: 232.
Klinicheskie rekomendatsii dlya pediatrov. Detskaya revmatologiya: Yuvenilnyiy dermatomiozit. Pod red AA Baranova, EI Alekseevoy. 2011. Moskva, Soyuz pediatrov Rossii: 240.
Klinicheskie rekomendatsii po detskoy kardiologii i revmatologii : Rossiyskie rekomendatsii razrabotanyi Komitetom ekspertov Vserossiyskoy obschestvennoy organizatsii Assotsiatsii detskih kardiologov Rossii. Pod red MA Shkolnikovoy, EI Alekseevoy. 2011. Moskva, Assotsiatsiya detskih kardiologov Rossii: 512.
Klinicheskie rekomendatsii. Revmatologiya. Pod red EL Nasonova. 2005. Moskva, GEOTAR-Media: 288.
Maslieva RI, Lyiskina GA, Ryabova TV. 2003. Lechenie yuvenilnogo dermatomiozita. PF. 4: 51—58.
Nasonov EL, Antelava OA. 2008. Idiopaticheskie vospalitelnyie miopatii. Natsionalnoe rukovodstvo po revmatologi. Pod red EL Nasonov, VA Nasonova. Moskva, GEOTAR-Media: 502—17.
Antelava OA, Bondarenko IB, Hitrov AN, Nasonov EL. 2008. Porazhenie dyihatelnoy sistemyi pri polimiozite/dermatomiozite. Russkiy med zhurn. 16(24): 1633—7.
Problemni pytannia diahnostyky i likuvannia systemnykh zakhvoriuvan spoluchnoi tkanyny u ditei. Materialy symp. DU «In-t okhorony zdorovia ditei ta pidlitkiv NAMN Ukrainy»; redkol. MM Koreniev (vidp red) et al. 2013. Kyiv: 243.
Radenska-Lopovok SG. 2011. Osnovnyie raznovidnosti vospalitelnyih miopatiy: morfologicheskaya differentsialnaya diagnostika. Nervno-myishechnyie bolezni. 1: 5—8.
Rukovodstvo po detskoy revmatologii. Yuvenilnyiy dermatomiozit. Pod red NA Geppe, NS Podchernyaevoy, GA Lyiskinoy. 2011. Moskva, GEOTAR-Media: 720.
Refteri ET, Lim E. 2008. Differentsialnyiy diagnoz. Per s angl. Moskva, MEDpress-inform: 511.
Berezhnoi VV, Kozhara YuA, Mihnusheva OS, Streltsova SV, Egorova LN. 2014. Case of progressive ossifying heteroplasia (POH) in childat the age of 1 year and 3 monthes. Sovremennaya pediatriya. 1: 44—48.
Sterling Dzh Vest. 2001. Sekretyi revmatologi. Moskva, Binom: 768.
Albayda J, Christopher-Stine L. 2012. Novel approaches in the treatmentof myositis and myopathies. Ther Adv Musculoskelet Dis: 1—9.
Blotman F, Branco J. 2007. Fibromyalgia — Daily Aches and Pain. Chantilly, France, Editions Privat: 253.
Chiu YE, Co DO. 2011. Juvenile dermatomyositis: immunopathogenesis, role of myositis-specific autoantibodies, and review of rituximab use. Pediatr Dermatol. 28: 357—67. https://doi.org/10.1111/j.1525-1470.2011.01501.x; PMid:21793879
Dalakas MC. 2010. Immunotherapy of myositis: issues, concerns and future prospects. Nature Rev. Rheumatol. 6: 129—37. https://doi.org/10.1038/nrrheum.2010.2; PMid:20125096
Gazeley DJ, Cronin ME. 2011. Diagnosis and treatment of the idiopathic inflammatory myopathies. Ther Adv Musculoskelet Dis. 3: 315—24. https://doi.org/10.1177/1759720X11415306; PMid:22870489 PMCid:PMC3383495
Hakim AJ, Clunie GRP. 2008. Oxford Handbook of Rheumatology. 2nd ed. Oxford, Oxford medical publications: 640.
Kliegman RM et al. 2011. Juvenile dermatomyositis. Nelson text-book of pediatrics, nineteenth edition. 153.
Katz U, Shoefeld Y, Zandman-Goddard G. 2011. Update on intravenous immunoglobulins (IVIg) mechanisms of action and off-label use in autoimmune diseases. Curr Pharmaceut Des. 17: 3166—75. https://doi.org/10.2174/138161211798157540; PMid:21864262
Kulkarni HS, Aggarwal R. 2011. Successful treatment of acute respiratory failure using rituximab and cyclophosphamide as a combination immunosuppressive regimen in a ventilator-dependent patient having antisynthetase syndrome. Am J Respir Crit Care Med. 183: 5661. https://doi.org/10.1164/ajrccm-conference.2011.183.1_meetingabstracts.a5661
Mastaglia FL. 2008. Inflammatory muscle diseases. Neurol India. 56: 263—70. https://doi.org/10.4103/0028-3886.43444; PMid:18974552
Musuruana JL, Cavallasca JA. 2011. Abatacept for treatment of refractory polymyositis. Joint Bone Spine Rev Rhum. 78: 431—2. https://doi.org/10.1016/j.jbspin.2011.03.022; PMid:21550833
Primer on Rheumatic Diseases. Kippel JH (ed). 12th ed. 2001. Atlanta, Arthritis Foundation: 703.
Quick A, Tandan R. 2011. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease. Curr Rheumatol Rep. 13: 192—8. https://doi.org/10.1007/s11926-011-0171-0; PMid:21503696
Oddis CV, Reed AM, Aggarwal R, Rider LG et al. 2013. Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis. A randomized, placebo-phase trial. Arthr And rheum. 65(2): 314—24. https://doi.org/10.1002/art.37754; PMid:23124935 PMCid:PMC3558563
Stubgen JP. 2011. Tumor necrosis factor-alpha as a potential therapeutic target in idiopathic inflammatory myopathies. J Neurol. 258: 961—70. https://doi.org/10.1007/s00415-011-5907-2; PMid:21253756
Narazaki M, Hagihara K, Shima Y et al. 2011. Therapeutic effect of tocilizumab on two patients with polymyositis. Rheumatology (Oxford). 50: 1344—6. https://doi.org/10.1093/rheumatology/ker152; PMid:21515628
Visser M. 2013. The efficacy of rituximab in refractory myositis: The Jury is still out. Arthr and rheum. 65(2): 303—6. https://doi.org/10.1002/art.37758; PMid:23125047
